Réf :HematoStat.net ; 1 (11) : V27 Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson PA, Kantarjian HM, Keating MJ, Burger JA. Ibrutinib induces durable remissions in […]

Treating lymphoma is now a bit EZ-er Réf :HematoStat.net : 1 (11) : V26 DOI: 10.1182/bloodadvances.2020002773

CAR T-cell Therapy for Secondary CNS DLBCL Réf :HematoStat.net : 1 (11) : V25 DOI: 10.1182/bloodadvances.2021005292 

SARS-CoV-2-inducedremission of Hodgkin lymphoma Réf :HematoStat.net : 1 (11) : V24 DOI: 10.1111/bjh.17116 

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma Réf :HematoStat.net : 1 (11) : V23 DOI: 10.3324/haematol.2020.254045

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas Réf :HematoStat.net : 1 (11) : V22 DOI: 10.3324/haematol.2019.238675 

The role of PET in first-line treatment of Hodgkin lymphoma Réf :HematoStat.net : 1 (11) : V21 DOI: 10.1016/S2352-3026(20)30357-4

Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia Réf :HematoStat.net : 1 (11) : V20 DOI: 10.1056/NEJMoa2031298

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy Réf :HematoStat.net : 1 (11) : V19 DOI: 10.1056/NEJMc2030164

Réf. :HematoStat.net ; 1 (1) : V18 Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner […]